Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

BRCA1 mutations in southern England

D M Eccles1, P Englefield, M A Soulby

  • 1Human Genetics, Level G Princess Ann Hospital, Southampton, UK.

British Journal of Cancer
|July 2, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Final Results of the Prospective FH02 Mammographic Surveillance Study of Women Aged 35-39 at Increased Familial Risk of Breast Cancer.

EClinicalMedicine·2019
Same author

The presentation, management and outcome of inflammatory breast cancer cases in the UK: Data from a multi-centre retrospective review.

Breast (Edinburgh, Scotland)·2018
Same author

Genetic testing in a cohort of young patients with HER2-amplified breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Understanding of BRCA VUS genetic results by breast cancer specialists.

BMC cancer·2015
Same author

BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Family history and outcome of young patients with breast cancer in the UK (POSH study).

The British journal of surgery·2015

Screening for BRCA1 mutations in breast cancer patients can be cost-effective when targeting specific high-risk groups. This approach identifies key mutations, enabling a rational strategy for public healthcare genetic testing.

Area of Science:

  • Genetics
  • Oncology
  • Public Health

Background:

  • Implementing genetic testing for hereditary breast and ovarian cancer within public healthcare requires cost-effective mutation analysis.
  • BRCA1 gene mutations are significant contributors to hereditary breast and ovarian cancer risk.

Purpose of the Study:

  • To establish parameters for a cost-effective regional BRCA1 mutation analysis strategy.
  • To evaluate the frequency and spectrum of BRCA1 mutations in different breast cancer patient cohorts.

Main Methods:

  • Screening of 230 breast cancer patients from the Wessex region for BRCA1 mutations.
  • Analysis of mutation prevalence in consecutive cases diagnosed under 40, bilateral breast cancer cases, and genetics clinic patients with a family history.

Related Experiment Videos

Main Results:

  • BRCA1 truncating mutations were found in 6.5% of women diagnosed under 40, 4.9% of bilateral breast cancer cases, and 26.6% of genetics clinic patients.
  • Ten different mutations were identified, with three accounting for 59% of affected families.
  • Population-wide BRCA1 screening is prohibitively expensive, but cohort screening is feasible.

Conclusions:

  • Targeted screening of selected patient cohorts for BRCA1 mutations is a cost-effective strategy for public healthcare.
  • This approach reduces costs, minimizes misinterpretation risks, and clarifies clinical benefits for hereditary cancer predisposition.
  • A rational approach to mutation analysis is essential for integrating genetic testing into public health systems.